Drug survival, discontinuation rates, and safety profile of secukinumab in real‐world patients: a 152‐week, multicenter, retrospective study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Drug survival, discontinuation rates, and safety profile of secukinumab in real‐world patients: a 152‐week, multicenter, retrospective study

Published:2020-03-15 Issue:5 Volume:59 Page:633-639
ISSN:0011-9059
Container-title:International Journal of Dermatology
language:en
Short-container-title:Int J Dermatol

Author:

Ruiz‐Villaverde Ricardo¹²^ORCID,Rodriguez‐Fernandez‐Freire Lourdes³,Galán‐Gutierrez Manuel⁴,Armario‐HIta Jose C.⁵,Martinez‐Pilar Leandro⁶

Affiliation:

1. UGC Dermatología Hospital Universitario San Cecilio Granada Spain

2. Instituto de Investigación Biosanitaria ibs.GRANADA Granada Spain

3. UGC Dermatología Hospital Universitario Virgen del Rocio Sevilla Spain

4. UGC Dermatología Hospital Universitario Reina Sofía Córdoba Spain

5. UGC Dermatología Hospital Universitario Puerto Real Cádiz Spain

6. UGC Dermatología Hospital Universitario Carlos Haya Málaga Spain

Publisher

Wiley

Subject

Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ijd.14819

Reference30 articles.

2. Contrasting pathogenesis of atopic dermatitis and psoriasis—Part I: Clinical and pathologic concepts

3. Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study)

4. The 3 major types of innate and adaptive cell-mediated effector immunity

5. Mechanisms of immune regulation in allergic diseases: the role of regulatory T and B cells

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug Survival of IL-17 and IL-23 Inhibitors for Psoriasis: A Systematic Review and Meta-Analysis;Drugs;2024-04-17

2. Dose reduction is a feasible strategy in patients with plaque psoriasis who achieve sustained response with secukinumab: a retrospective, multicenter cohort study in daily practice setting;International Journal of Dermatology;2024-01-02

3. Durability and long-term outcomes of biologic therapies in psoriasis;Expert Review of Clinical Immunology;2023-08-25

4. Long-term efficacy and safety of secukinumab in real life: a 240 weeks multicenter study from Southern Italy;Journal of Dermatological Treatment;2023-05-16

5. Secukinumab in Patients with Psoriasis and a Personal History of Malignancy: A Multicenter Real-Life Observational Study;Dermatology and Therapy;2022-09-28

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3